by San Rocco Therapeutics | May 19, 2026 | News
San Rocco Therapeutics Unveils Promising “MiNiRoLu” Gene Therapy Data at ASGCT According to the company, the SRT8 “MiNiRoLu” vector demonstrated approximately 30% higher functional titer, 35% greater transduction efficiency, and roughly 40% higher β-globin expression...
by San Rocco Therapeutics | Apr 30, 2026 | News
SRT announces their Next-Generation Gene Therapy for Hemoglobin Disorders San Rocco Therapeutics (SRT) today announced two abstracts at the upcoming 2026 ASGCT Annual Meeting highlighting its gene therapy platform, MiNiRoLu (SRT8-T87Q), and a companion diagnostic for...
by San Rocco Therapeutics | Apr 29, 2026 | News
SRT at ASGCT | Abstract 3507 3507 A lentiviral vector with enhanced titer and T87Q β-globin expression for treatment of severe β-hemoglobin disorders INTRODUCTIONSickle cell disease (SCD) and β-thalassemia are caused by defect or deficiency in adult β-globin....
by San Rocco Therapeutics | Apr 29, 2026 | News
SRT at ASGCT | Abstract 465 465 A RT-qPCR assay for precise detection and absolute quantification of the T87Q β-globin variant in erythroid progeny of lentivirus transduced human CD34+ cells INTRODUCTIONLentiviral vectors (LVV) encoding for erythroid-specific...
by San Rocco Therapeutics | Apr 10, 2026 | News
Gene and Cell Therapy Spotlighted in Resurrection LA Premiere May 1–7 as San Rocco Therapeutics Advances Toward a Cure San Rocco Productions announces the upcoming premiere of Resurrection, a feature film inspired by the real-world scientific and medical journey to...
by San Rocco Therapeutics | Feb 25, 2026 | News
Professors Frank Park and Andrew Wilber Win the Prestigious 2025 Orphan Dream Award Biomedical researchers Frank Park, Ph.D., an Associate Professor at the University of Tennessee Health Science Center (UTHSC), and Andrew Wilber, Ph.D., an Associate Professor at...
